**Core Concept**
The patent ductus arteriosus (PDA) is a congenital heart defect where the ductus arteriosus, a normal fetal shunt between the aorta and pulmonary artery, fails to close after birth. This results in excessive blood flow to the lungs, leading to respiratory distress and other systemic complications.

**Why the Correct Answer is Right**
The use of indomethacin is a common pharmacological approach to close a PDA in newborns. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis, which is essential for maintaining the ductus arteriosus in a patent state. By reducing prostaglandin levels, indomethacin promotes the closure of the ductus arteriosus. This mechanism is particularly effective in the first few weeks of life, when the ductus arteriosus is still patent.

**Why Each Wrong Option is Incorrect**
**Option A:** Furosemide is a loop diuretic used to treat fluid overload, but it does not have a role in closing a PDA.
**Option B:** Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation, but it does not affect the closure of a PDA.
**Option C:** Dobutamine is a beta-adrenergic agonist used to increase cardiac contractility, but it does not promote the closure of a PDA.

**Clinical Pearl / High-Yield Fact**
In the neonatal period, the use of prostaglandin E1 (PGE1) is often employed to keep a PDA patent, allowing for ductal-dependent congenital heart defects to be diagnosed and treated.

**Correct Answer:** A. Indomethacin